Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Projan

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Current Pharmaceutical Design|June 8, 2002
Genomics in anti-infective drug discovery--getting to endgameSteven A Haney, Lefa E Alksne, Paul M Dunman, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|September 10, 2003
Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patientLaszlo Papp, David F McNeeley, Steven J Projan, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Charles R Dean, Melissa A Visalli, Steven J Projan, et al.
Journal of Bacteriology|January 5, 2005
Comparative genomics of Staphylococcus aureus musculoskeletal isolatesJames E Cassat, Paul M Dunman, Fionnuala McAleese, et al.
Journal of Bacteriology|December 4, 2004
Effect of mild acid on gene expression in Staphylococcus aureusBrian Weinrick, Paul M Dunman, Fionnuala McAleese, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecyclineFionnuala McAleese, Peter Petersen, Alexey Ruzin, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogensPeter J Petersen, Patricia A Bradford, William J Weiss, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infectionWilliam J Weiss, Eileen Lenoy, Timothy Murphy, et al.
Biochimica Et Biophysica Acta|May 3, 2003
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureusAlexey Ruzin, Anatoly Severin, Soraya L Moghazeh, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2008
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489Peter J Petersen, C Hal Jones, Aranapakam M Venkatesan, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Current Pharmaceutical Design|June 8, 2002
Genomics in anti-infective drug discovery--getting to endgameSteven A Haney, Lefa E Alksne, Paul M Dunman, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|September 10, 2003
Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patientLaszlo Papp, David F McNeeley, Steven J Projan, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Charles R Dean, Melissa A Visalli, Steven J Projan, et al.
Journal of Bacteriology|January 5, 2005
Comparative genomics of Staphylococcus aureus musculoskeletal isolatesJames E Cassat, Paul M Dunman, Fionnuala McAleese, et al.
Journal of Bacteriology|December 4, 2004
Effect of mild acid on gene expression in Staphylococcus aureusBrian Weinrick, Paul M Dunman, Fionnuala McAleese, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecyclineFionnuala McAleese, Peter Petersen, Alexey Ruzin, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogensPeter J Petersen, Patricia A Bradford, William J Weiss, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infectionWilliam J Weiss, Eileen Lenoy, Timothy Murphy, et al.
Biochimica Et Biophysica Acta|May 3, 2003
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureusAlexey Ruzin, Anatoly Severin, Soraya L Moghazeh, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2008
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489Peter J Petersen, C Hal Jones, Aranapakam M Venkatesan, et al.
Pageof 3